[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Tiantan Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":600},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,233,0,25,[9,44,75,106,126,150,173,195,223,253,275,292,312,335,354,373,404,426,452,469,494,515,536,558,578],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100053256","phase-1-venlafaxine-combined-with-education-and-behavioral-intervention-for-bladder-pain-syndrome-100053256",false,"NCT07698626","Venlafaxine Combined With Education and Behavioral Intervention for Bladder Pain Syndrome","A Multicenter, Open-label, Observer-blinded Randomized Controlled Trial Comparing the Efficacy and Safety of Venlafaxine Plus Education and Behavioral Modification Program Versus Education and Behavioral Modification Program Alone in Adults With Interstitial Cystitis\u002FBladder Pain Syndrome","VEN-BPS","Inclusion Criteria:\n\nAge ≥ 18 years (all genders) Confirmed IC\u002FBPS diagnosis fulfilling AUA 2015 and ESSIC standardized diagnostic criteria, ruled out confounding urologic disorders Predominant lower urinary tract symptoms present for most days in the past 3 months Baseline bladder\u002Fpelvic pain and urinary frequency score ≥ 3 points on 0-10 Likert scale within prior 4 weeks\n\nExclusion Criteria:\n\nSymptomatic urethral stricture Active degenerative\u002Finflammatory neurological disease altering bladder\u002Fintestinal function Uncontrolled active autoimmune disease or systemic infection Medical history of pelvic tuberculosis, pelvic radiotherapy or chemotherapy-induced cystitis History of non-cutaneous malignant tumors Current diagnosis of severe psychiatric disorders (major depressive disorder, bipolar disorder, schizophrenia, psychotic disorders) Clinically significant moderate-severe cardiac, pulmonary, hepatic or renal insufficiency Documented hypersensitivity to venlafaxine or other SNRI drugs Concurrent regular use of antibiotics or NSAIDs throughout trial period Pregnancy or breastfeeding state at screening","ALL","18 Years","80 Years",{"count":22,"type":23},140,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","This study aims to compare two treatment plans for adults with bladder pain syndrome (also called interstitial cystitis), a disease that causes long-lasting bladder pain, frequent urination and urgent need to pee. All participants will receive standardized patient education and behavioral training to relieve urinary discomfort. Half of the participants will only get this behavioral intervention, while the other half will take oral venlafaxine in addition to the same behavioral training for 12 weeks. We will check patients' pain levels, urination frequency, sleep quality, mood and daily life ability at 1, 2, 6 and 12 weeks of treatment. The main goal is to see whether adding venlafaxine can better ease bladder pain and urinary symptoms without obvious side effects. This research will provide safer and more effective treatment suggestions for patients with bladder pain syndrome.",[29,30,31],"Bladder Pain Syndrome","Chronic Pelvic Nociplastic Pain","Interstitial Cystitis","NOT_YET_RECRUITING","2026-07-07",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":23},"2026-12-31",{"date":40,"type":23},"2027-12-31",{"name":42,"class":43},"Beijing Tiantan Hospital","OTHER",{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":52,"targetDuration":4,"studyType":24,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100633461","phase-3-efficacy-and-safety-of-minocycline-in-patients-with-acute-ischaemic-stroke-receiving-intravenous-thrombolysis-100633461","NCT07526987","Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis","Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis (EMPHASIS-2): A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Trial","EMPHASIS-2","Inclusion Criteria:\n\n1. Age between 18 and 80 years;\n2. Patients with acute ischaemic stroke confirmed by CT or MRI;\n3. Having received or planning to receive intravenous thrombolysis within 4.5 hours of onset or within an extended window of 4.5-24 hours based on guideline recommendations (The intravenous thrombolytic drugs include: alteplase, tenecteplase, reteplase or recombinant human prourokinase);\n4. The study drug can be applied before intravenous thrombolysis or within 2 hours after the initiation of intravenous thrombolysis;\n5. 6≤NIHSS≤25, and Ia≤1;\n6. Signed informed consent.\n\nExclusion Criteria:\n\n1. mRS score ≥ 2 prior to onset of the current stroke;\n2. History of pseudomembranous colitis or antibiotic-associated colitis;\n3. Known allergy or intolerance to tetracycline antibiotics or any component of minocycline;\n4. Known resistance to other tetracyclines;\n5. Use of tetracycline antibiotics within the past 7 days;\n6. Presence of a known community-acquired bacterial infection (e.g., pneumonia, urinary tract infection) or any other concurrent infection requiring antibiotic treatment;\n7. History of intracranial hemorrhagic disease within the past 3 months, for example, parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural or epidural hematoma.\n8. Malformation, tumor, abscess, or other major non-ischaemic brain diseases (e.g., multiple sclerosis, other intracranial space-occupying lesions) on baseline cranial CT or MRI;\n9. Rare or unknown etiology of large vessel occlusion (e.g., arterial dissection, vasculitis);\n10. History of systemic lupus erythematosus;\n11. Known severe hepatic insufficiency (ALT or AST \\> 3 times of the upper limit of normal), severe renal insufficiency (creatinine \\> 3.0 mg\u002FdL \\[265.2 μmol\u002FL\\], estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73m², or have received dialysis before randomization);\n12. Use of tretinoin, androgen or antiandrogen treatment (e.g., anabolic steroids, spironolactone) within the past 3 months;\n13. Pregnant, breastfeeding, or of childbearing potential who are unwilling to use effective contraception throughout the study;\n14. Presence of a severe non-cardio-cerebrovascular disease with a life expectancy of less than 6 months;\n15. Participation in any other clinical trial within the past 30 days;\n16. Any other condition that is not suitable for participating in this clinical trial, such as inability to understand or follow the study procedures due to physical, cognitive, emotional, or mental disorders.",{"count":53,"type":23},934,[55],"PHASE3","The aim of this study is to assess the efficacy and safety of minocycline in improving functional outcome among patients with acute ischaemic stroke receiving intravenous thrombolysis.",[58],"Ischaemic Stroke",[60,61,62,63,64],"Ischaemic stroke","Intravenous thrombolysis","Minocycline","Randomized Controlled Trial","Functional outcome","RECRUITING","2026-06-30",{"date":68,"type":36},"2026-07-01",{"date":70,"type":36},"2026-06-05",{"date":72,"type":23},"2028-12-31",{"name":42,"class":43},3,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100642376","endovascular-therapy-for-cerebral-vasospasm-after-aneurysmal-subarachnoid-hemorrhage-100642376","NCT07643922","Endovascular Therapy for Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage","Endovascular Therapy for Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage: The RESCUE-CV Randomized Trial","RESCUE-CV","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n1. Aged 18 to 80 years.\n2. SAH confirmed by cranial CT, with an intracranial aneurysm identified by CTA, MRA, or DSA and determined to be the source of bleeding.\n3. Prior treatment of the aneurysm by endovascular intervention or surgical clipping.\n4. Evidence suggestive of CVS within 14 days after onset, defined by at least one of the following:\n\n   1. Clinical deterioration, including a decrease in GCS score of \\>2 points and\u002For a new focal neurological deficit not attributable to another known neurological cause;\n   2. TCD confirmed vasospasm, defined as mean flow velocity (MFV) \\>120 cm\u002Fs in the middle cerebral artery (MCA) and Lindegaard ratio \\>3, after excluding other causes of increased flow velocity such as anemia or fever;\n   3. Vasospasm confirmed by DSA or CTA.\n\nExclusion Criteria:\n\n1. Hunt-Hess grade 5 with critical illness and inability to tolerate intervention.\n2. Contraindications to milrinone, including milrinone allergy, aortic or pulmonary valve stenosis, obstructive hypertrophic cardiomyopathy, acute coronary syndrome, or malignant arrhythmia.\n3. Perioperative procedure-related complications that may interfere with study assessment, such as significant stenosis of the parent artery.\n4. Irreversible cerebral infarction involving the entire vascular territory affected by vasospasm.\n5. Poor blood pressure control, defined as systolic blood pressure \\\u003C100 mmHg.\n6. Non-aneurysmal SAH, including hemorrhage due to arteriovenous malformation, vasculitis, tumor bleeding, trauma, or other non-spontaneous causes, or cases without an identified bleeding source.\n7. Other severe neurological disorders with substantial pre-existing disability (mRS \\>3), such as progressive cognitive impairment or status epilepticus.\n8. Severe systemic disease, including significant cardiac, hepatic, renal, or psychiatric disorders.\n9. Pregnant or breastfeeding women, or women planning pregnancy during the study period.\n10. Any other condition considered by the investigators to make the patient unsuitable for participation or likely to limit compliance with study procedures.\n11. Current participation in another interventional clinical study, inability to complete follow-up assessments, or failure to provide informed consent.",{"count":84,"type":23},306,[86],"NA","Cerebral vasospasm is a common and serious complication after aneurysmal subarachnoid hemorrhage and is an important cause of delayed cerebral ischemia and poor neurological outcomes. Although standardized medical management is widely used, effective treatment options for cerebral vasospasm remain limited.\n\nEndovascular treatment, including intra-arterial drug infusion and mechanical angioplasty, may relieve vasospasm and improve cerebral perfusion after aneurysmal subarachnoid hemorrhage. However, most available evidence comes from retrospective or observational studies, and high-quality randomized evidence remains insufficient. Milrinone is a phosphodiesterase inhibitor with multiple potentially beneficial effects, including vasodilation, positive inotropic activity, anti-inflammatory properties, and endothelial protection. These effects may make milrinone a promising therapeutic agent for relieving cerebral vasospasm, reducing delayed cerebral ischemia, and ultimately improving clinical outcomes after aneurysmal subarachnoid hemorrhage.\n\nThis study is a multicenter, prospective, randomized controlled clinical trial designed to evaluate whether early continuous milrinone-based endovascular therapy improves outcomes in patients with cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Eligible participants will be randomly assigned to receive either standardized medical management alone or milrinone-based endovascular therapy plus standardized medical management. In the intervention group, patients will receive intra-arterial milrinone during endovascular treatment, with mechanical angioplasty when clinically indicated, followed by continuous intravenous milrinone infusion for 72 hours after intra-arterial administration.\n\nThe study will evaluate whether this continuous treatment strategy reduces poor neurological outcomes at 3 months after randomization. It will also assess the effects of treatment on delayed cerebral ischemia, vasospasm resolution, cognitive function, quality of life and so on. The results of this trial may provide high-quality evidence for early continuous milrinone-based endovascular therapy as a treatment strategy for cerebral vasospasm after aneurysmal subarachnoid hemorrhage.",[89,90],"Subarachnoid Hemorrhage, Aneurysmal","Cerebral Vasospasm After Subarachnoid Hemorrhage",[92,93,94,95,96],"aneurysmal subarachnoid hemorrhage","Cerebral vasospasm","Milrinone","Endovascular Therapy","Outcomes","2026-06-25",{"date":99,"type":36},"2026-06-29",{"date":101,"type":36},"2026-06-03",{"date":103,"type":23},"2029-12-31",{"name":42,"class":43},2,{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":24,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":125,"locationsCount":4},"100644676","efficacy-and-safety-of-oral-antiviral-therapy-for-idiopathic-trigeminal-neuralgia-100644676","NCT07673549","Efficacy and Safety of Oral Antiviral Therapy for Idiopathic Trigeminal Neuralgia","Efficacy and Safety of Oral Antiviral Drug Combined With Carbamazepine Versus Celecoxib Combined With Carbamazepine in the Treatment of Idiopathic Trigeminal Neuralgia: A Multicenter, Randomized Controlled Trial","ANT-TN","Inclusion Criteria:\n\n1. Diagnosed with idiopathic trigeminal neuralgia according to standard clinical criteria.\n2. No secondary etiology confirmed by cranial imaging.\n3. No severe systemic disease or immune system disease.\n4. Voluntary participation and signed informed consent.\n\nExclusion Criteria:\n\n1. Secondary trigeminal neuralgia of any cause.\n2. Active herpes zoster infection recently.\n3. Severe hepatic or renal insufficiency or contraindications to study drugs.\n4. Unable to complete questionnaire evaluation independently.\n5. Pregnancy or lactation state. -",{"count":115,"type":23},165,[86],"This is a multicenter, prospective, randomized, controlled trial. A total of 165 patients with idiopathic trigeminal neuralgia will be enrolled and randomly divided into three groups at a 1:1:1 ratio. The aim is to compare the efficacy and safety of conventional carbamazepine monotherapy, carbamazepine combined with oral antiviral therapy, and carbamazepine combined with anti-inflammatory therapy in pain relief, quality of life improvement and adverse event profiles.",[119],"Idiopathic Trigeminal Neuralgia","2026-06-23",{"date":99,"type":36},{"date":123,"type":23},"2026-08-31",{"date":40,"type":23},{"name":42,"class":43},{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":24,"phases":136,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},"100643677","efficacy-of-pregabalin-for-patients-with-irritable-bowel-syndrome-100643677","NCT07635394","Efficacy of Pregabalin for Patients With Irritable Bowel Syndrome","Efficacy and Safety of Pregabalin in Patients With Irritable Bowel Syndrome : A Multi-center Prospective Randomized Open Blinded End-point Trial","Inclusion Criteria:\n\n1. Age range: 18-70 years old;\n2. According to the Rome IV diagnostic criteria for IBS, the screening result is positive;\n3. Mild to moderate IBS patients assessed based on the IBS-SSS.\n\nExclusion Criteria:\n\n1. Concurrent gastrointestinal conditions presenting with symptoms potentially overlapping with those of IBS, significant medical comorbidities;\n2. Severe mental disorders associated with marked personality disturbances, active suicidal thoughts or any self harm episodes within the preceding 12 months;\n3. Current or intended pregnancy or lactation;\n4. Cognitive impairment;\n5. Recent use of pregabalin (within 30 days) or known allergy to pregabalin;\n6. Concomitant use of medications that may interact with the study drug, mimic its effects, or aggravate expected adverse reactions (including but not limited to rosiglitazone, pioglitazone, opioids, anxiolytics, non opioid analgesics, mexiletine, dextromethorphan, and sedative hypnotics);\n7. Use of IBS specific agents such as alosetron;\n8. Consumption exceeding 50 units of alcohol weekly (where 1 unit corresponds to 10 mL of pure alcohol).","70 Years",{"count":135,"type":23},258,[86],"To explore the efficacy of pregabalin for patients with irritable bowel syndrome (IBS).",[139],"Irritable Bowel Syndrome (IBS)",[141,142],"Irritable Bowel Syndrome","pregabalin",{"date":97,"type":36},{"date":145,"type":36},"2026-04-07",{"date":147,"type":23},"2029-03-31",{"name":42,"class":43},1,{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":18,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":24,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":149},"100612165","phase-3-jiedu-huayu-oral-prescription-in-the-treatment-of-intracranial-hemorrhage-associated-with-cerebral-amyloid-angiopathy-100612165","NCT07250035","Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study of Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy","CHN-CAA","Inclusion Criteria:\n\n* ① Possible or very likely CAA-ICH;\n\n  * Within 7 days of onset; ③ Primary supratentorial intracerebral hemorrhage (bleeding volume ≤40ml);\n\n    * GCS≥8 points;\n\n      * NIHSS score ≤25 points; ⑥50≤age≤90 years old; ⑦ Gender is not limited; ⑧ The subject or their legal representative gives informed consent and signs the informed consent form.\n\nExclusion Criteria:\n\n* Those who are known to be allergic to the components of the traditional Chinese medicine compound used in the experiment;\n\n  * It is known that after treatment with vascular malformations, aneurysms, coagulation disorders, anticoagulant or antiplatelet drugs, Intracranial conditions caused by clear etiologies such as thrombolytic therapy, post-infarction hemorrhage transformation, hematological diseases, moyamoya disease, etc;\n\n    * Patients with traumatic intracranial hemorrhage;\n\n      * Patients with active peptic ulcers or other clear tendencies of rebleeding;\n\n        * Patients with severe liver or kidney dysfunction (Note: Severe liver dysfunction is defined as ALT or AST being greater than.\n\n          ⑥ Those who have received or are planning to undergo surgical treatment;\n\n          ⑦ Those who suffer from other life-threatening serious diseases and have an expected survival time of less than six months;\n\n          ⑧ Other conditions that significantly limit the evaluation of neurological function, prevent the completion of cranial magnetic resonance imaging, or affect the follow-up of patient;\n\n          ⑨ Pregnant women, those planning to become pregnant or lactating women;\n\n          ⑩Those who are currently participating in other interventional clinical trials.","50 Years","90 Years",{"count":161,"type":23},436,[55],"Cerebral hemorrhage, as a serious cerebrovascular disease, has the highest disability rate and mortality rate among all types of cerebrovascular diseases .It has brought a heavy burden to society. In China, the incidence of cerebral hemorrhage is much higher than that in Europe and America, and cerebral amyloid angiopathy (CAA) is one of the causes of primary cerebral hemorrhage However, there are relatively few related studies. Therefore, the research object of this subject focuses on patients with cerebral amyloid angiopathy, in view of their high recurrence rate of vascular events and the lack of treatment methods.It aims to deeply explore the detoxification and blood stasis removal treatment plan combining traditional Chinese and Western medicine to reduce vascular events for patients.",[165],"Cerebral Amyloid Angiopathy",{"date":167,"type":36},"2026-06-24",{"date":169,"type":36},"2026-01-30",{"date":171,"type":23},"2028-11-30",{"name":42,"class":43},{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":24,"phases":182,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":149},"100605079","the-efficacy-and-safety-of-pregabalin-and-mirogabalin-in-patients-with-fibromyalgia-100605079","NCT07157852","The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia","Comparing the Efficacy and Safety of Pregabalin Monotherapy Versus Other Neuromodulatory Drugs (Mirogabalin) in the Treatment of Fibromyalgia: A Multicenter Clinical Study","Inclusion Criteria:\n\n* Newly diagnosed with FM according to the 2016 Revisions to the 2010\u002F2011 FM diagnostic criteria;\\[1\\]\n* Aged over 18 years old;\n* Suffering from moderate to severe FM, refractory to non-pharmacological interventions and without prior exposure to recommend pharmacological treatments for FM;\n* Baseline numeric rating scale (NRS) score of 4 or higher;\n* Aspartate aminotransferase and alanine aminotransferase levels below twice the upper limit of normal range;\n* Estimated glomerular filtration rate (eGFR) of at least 30 mL\u002Fmin\u002F1.73 m²;\n* Willingness to provide informed consent and adequate cognitive and language capabilities to meet all study requirements;\n\nExclusion Criteria:\n\n* Previous allergic reactions to pregabalin, mirogabalin, or any of their excipients;\n* Prior diagnosis of epilepsy or depression requiring antidepressant therapy;\n* Women who are pregnant or breastfeeding;\n* Has severe systemic illnesses, such as poorly controlled hypertension, poorly controlled diabetes mellitus, or significant cardiac impairment;\n* Suffering from acute or chronic pain disorders other than FM.",{"count":181,"type":23},674,[86],"Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. Mirogabalin, a new highly selective α2δ ligand, has shown potential in animal models or preliminary clinical trials, but there is insufficient evidence for its application in FM. This study aims to explore the effectiveness and safety of pregabalin or mirogabalin in treating FM, with the aim of providing a better treatment option for FM patients.",[185,186,187,188],"Fibromyalgia","Pregabalin","Mirogabalin","Pain",{"date":97,"type":36},{"date":191,"type":36},"2025-09-05",{"date":193,"type":23},"2027-08-31",{"name":42,"class":43},{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":24,"phases":205,"briefSummary":206,"conditions":207,"keywords":210,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":149},"100644479","phase-3-direct-angio-suite-acute-stroke-intervention-with-ctdsa-hybrid-emergency-stroke-unit-100644479","NCT07670065","Direct Angio Suite Acute Stroke Intervention With CT\u002FDSA Hybrid Emergency Stroke Unit","Direct Angio Suite Acute Stroke Intervention With CT\u002FDSA Hybrid Emergency Stroke Unit to Reduce Time to Endovascular Reperfusion for Acute Ischemic Stroke","Inclusion Criteria\n\n1. Age 18-60 years;\n2. Clinical diagnosis of acute ischemic stroke eligible for immediate endovascular treatment;\n3. Time from symptom onset or last known well ≤ 24 hours;\n4. Intravenous intracranial and cervical CT angiography completed;\n5. Confirmed target vessel occlusion amenable to endovascular intervention based on intravenous intracranial and cervical CT angiography findings;\n6. Written informed consent obtained from the patient or their legally authorized representative.\n\nExclusion Criteria\n\n1. Known contrast agent allergy;\n2. Renal insufficiency with GFR (glomerular filtration rate) \\\u003C 45 mL\u002Fmin\u002F1.73 m²;\n3. History of kidney transplantation;\n4. Concomitant diabetes mellitus with current use of metformin;\n5. Women who are pregnant, breastfeeding, or have a positive pregnancy test at admission;\n6. Refractory hypertension (defined as systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) (Note: patients may be enrolled if blood pressure is successfully reduced and maintained at an acceptable level with antihypertensive therapy);\n7. Intracranial space-occupying lesion or other conditions deemed unsuitable for endovascular intervention on imaging;\n8. Any other serious comorbidity or complication that may interfere with study conduct or evaluation.","60 Years",{"count":204,"type":23},232,[55],"This study investigates whether direct transfer to an emergency stroke unit equipped with NeuAngio-CT reduces time to endovascular reperfusion in patients with acute ischemic stroke and suspected intracranial large-vessel occlusion.Those aged 18-60 years with acute ischemic stroke who are eligible for endovascular thrombectomy within 24 hours of symptom onset will be enrolled. Participants will be randomly assigned to one of two groups. In the intervention group, participants will undergo femoral or radial artery puncture, followed by intracranial and cervical CT angiography with intra-arterial contrast injection (iacCTA) performed using the sliding-rail NeuAngio-CT, and subsequent thrombectomy guided by fused CTA-DSA images. In the control group, participants will receive intracranial and cervical CT angiography with intra-venous contrast injection and the thrombectomy will guided by standard DSA imaging without use of the sliding-rail CT. The primary endpoint is puncture-to-successful-reperfusion time (PRT); if successful reperfusion is not achieved, the end-of-procedure time will be used.",[208,209],"Acute Ischemic Stroke","Large Vessel Occlusion",[211,212,213,214],"Sliding CT\u002FDSA","One-stop Management","Mechanical Thrombectomy","Emergency Stroke Care","2026-06-21",{"date":217,"type":36},"2026-06-26",{"date":219,"type":23},"2026-06-08",{"date":221,"type":23},"2027-10-15",{"name":42,"class":43},{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":24,"phases":233,"briefSummary":234,"conditions":235,"keywords":240,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":149},"100641974","pre-incisional-infiltration-with-ropivacaine-plus-triamcinolone-for-relieving-postoperative-pain-after-laparoscopic-surgery-100641974","NCT07591233","Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Laparoscopic Surgery","The Efficacy and Safety of Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Postoperative Pain in Patients Undergoing Laparoscopic Surgery: a Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients scheduled for elective Laparoscopic Surgery for laparoscopic cholecystectomy, appendectomy, or hernia repair under general anesthesia;\n2. Ages 18 to 64 years old;\n3. American Society of Anesthesiologists (ASA) physical status of I-III;\n4. Patients must be able to understand nature and potential personal; consequences of the clinical trial and cooperation with follow-up investigations\n5. signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of allergies to experimental drugs such as opioids or steroids;\n2. Alcohol abuse; Long term use of opioid drugs (exceeding 2 weeks or 3 days per week for more than 1 month); Suspected use of sedatives and analgesics; Use analgesic drugs within 24 hours before surgery; Patients undergoing steroid therapy;\n3. Serious neurological disorders, severe liver and kidney dysfunction, heart failure, etc;\n4. Unable to use pain assessment scale;\n5. Pregnant or lactating patients.","64 Years",{"count":232,"type":23},150,[86],"Incisional infiltration is the simplest, safest, and most effective anesthesia method for preventing incision pain after laparoscopic surgery, but even using long-acting local anesthetics, the effectiveness of postoperative analgesia can only last for a relatively short period of time. Studies have shown that up to 80% of patients experience postoperative pain following laparoscopic surgery due to inflammation caused by surgical incisions and surrounding tissues, necessitating pharmacological relief. Inflammatory mediators released from the soft tissues around laparoscopic incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization. Preemptive incisional infiltration using local anesthetics with corticosteroids which have potent local anti-inflammatory properties may play a key role in preventing or reducing postoperative pain. The objective of this trial is to determine whether preemptive incisional infiltration with ropivacaine plus triamcinolone is superior to ropivacaine alone in relieving postoperative pain for adults undergoing laparoscopic surgery. We also compare the effects of the two intervention measures on postoperative pain management, patient safety, and recovery quality.",[236,237,238,239],"Laparoscopic Surgery","Laparoscopic Cholecystectomy","Appendectomy, Laparoscopic","Hernia Repair",[241,242,243,244],"Laparoscopic","Incisional infiltration","triamcinolone","postoperative pain","2026-06-16",{"date":247,"type":36},"2026-06-17",{"date":249,"type":36},"2026-06-01",{"date":251,"type":23},"2028-05-30",{"name":42,"class":43},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":230,"enrollmentInfo":260,"targetDuration":4,"studyType":24,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":274,"locationsCount":149},"100641875","pre-incisional-infiltration-with-ropivacaine-plus-diprospan-for-relieving-postoperative-pain-after-thoracoscopic-surgery-100641875","NCT07626489","Pre-incisional Infiltration With Ropivacaine Plus Diprospan for Relieving Postoperative Pain After Thoracoscopic Surgery","The Efficacy and Safety of Pre-incisional Infiltration With Ropivacaine Plus Diprospan in Patients Undergoing Video-assisted Thoracoscopic: a Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients scheduled for elective Video-assisted thoracoscopic surgery for wedge resection, segmentectomy and lobectomy of the lungs under general anesthesia;\n2. 8 to 64 years old\n3. American Society of Anesthesiologists (ASA) physical status of I-III\n4. Patients must be able to understand the nature and potential personal consequences of the clinical trial and cooperate with follow-up investigations\n5. signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of allergies to experimental drugs such as opioids or steroids;\n2. Alcohol abuse; Long term use of opioid drugs (exceeding 2 weeks or 3 days per week for more than 1 month); Suspected use of sedatives and analgesics; Use analgesic drugs within 24 hours before surgery; Patients undergoing steroid therapy;\n3. Serious neurological disorders, severe liver and kidney dysfunction, heart failure, etc;\n4. Unable to use pain assessment scale;\n5. Pregnant or lactating patients.",{"count":261,"type":23},100,[86],"Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy, but it is still reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process. If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Acute pain after VATS is mainly caused by the release of inflammatory mediators after soft tissue injury at the surgical site, which activates peripheral pain receptors and leads to abnormal action potentials transmitted along A δ and C fibers. Inflammatory mediators released from the soft tissues around incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization.\n\nIncisional infiltration is the simplest, safest, and most effective anesthesia method for preventing incision pain after VATS, but even using long-acting local anesthetics, the effectiveness of postoperative analgesia can only last for a relatively short period of time. To improve the efficiency of local incision infiltration in postoperative analgesia, at least two issues need to be addressed: prolonging the duration of analgesia and reducing inflammation of nerve surrounding tissues. Numerous studies have shown that glucocorticoids not only can achieve anti-inflammatory and analgesic effects by inhibiting inflammatory cytokines and inflammatory responses but also can prolong the duration of action of local anesthetics. Preemptive incisional infiltration using local anesthetics with corticosteroids which have potent local anti-inflammatory properties may play a key role in preventing or reducing postoperative pain. The objective of this trial is to determine whether preemptive incisional infiltration with ropivacaine plus diprospan is superior to ropivacaine alone in relieving postoperative pain for adults undergoing VATS. The investigators also compare the effects of the two intervention measures on postoperative pain management, patient safety, and recovery quality.",[265,266,267,268,269],"Video-assisted Thoracoscopic Surgery (VATS)","Wedge Resection","Segmentectomy","Lobectomy","Infiltration Anesthesia",{"date":247,"type":36},{"date":272,"type":23},"2026-05-30",{"date":251,"type":23},{"name":42,"class":43},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":230,"enrollmentInfo":282,"targetDuration":4,"studyType":24,"phases":283,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":291,"locationsCount":149},"100641734","pre-incisional-infiltration-with-ropivacaine-plus-diprospan-for-relieving-postoperative-pain-after-laparoscopic-surgery-100641734","NCT07626463","Pre-incisional Infiltration With Ropivacaine Plus Diprospan for Relieving Postoperative Pain After Laparoscopic Surgery","The Efficacy and Safety of Pre-incisional Infiltration With Ropivacaine Plus Diprospan in Patients Undergoing Laparoscopic Surgery: a Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients scheduled for elective Laparoscopic Surgery for laparoscopic cholecystectomy, appendectomy, or hernia repair under general anesthesia;\n2. Ages 18 to 64 years old;\n3. American Society of Anesthesiologists (ASA) physical status of I-III;\n4. Patients must be able to understand nature and potential personal; consequences of the clinical trial and cooperation with follow-up investigations;\n5. signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of allergies to experimental drugs such as opioids or steroids;\n2. Alcohol abuse; Long term use of opioid drugs (exceeding 2 weeks or 3 days per week for more than 1 month); Suspected use of sedatives and analgesics;\n3. Use analgesic drugs within 24 hours before surgery;\n4. Patients undergoing steroid therapy;\n5. Serious neurological disorders, severe liver and kidney dysfunction, heart failure, etc;\n6. Unable to use pain assessment scale;\n7. Pregnant or lactating patients.",{"count":232,"type":23},[86],"Incisional infiltration is the simplest, safest, and most effective anesthesia method for preventing incision pain after laparoscopic surgery, but even using long-acting local anesthetics, the effectiveness of postoperative analgesia can only last for a relatively short period of time. Studies have shown that up to 80% of patients experience postoperative pain following laparoscopic surgery due to inflammation caused by surgical incisions and surrounding tissues, necessitating pharmacological relief. Inflammatory mediators released from the soft tissues around laparoscopic incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization.\n\nNumerous studies have shown that glucocorticoids not only can achieve anti-inflammatory and analgesic effects by inhibiting inflammatory cytokines and inflammatory responses but also can prolong the duration of action of local anesthetics. Preemptive incisional infiltration using local anesthetics with corticosteroids which have potent local anti-inflammatory properties may play a key role in preventing or reducing postoperative pain. The objective of this trial is to determine whether preemptive incisional infiltration with ropivacaine plus diprospan is superior to ropivacaine alone in relieving postoperative pain for adults undergoing laparoscopic surgery. The investigators also compare the effects of the two intervention measures on postoperative pain management, patient safety, and recovery quality.",[236,286,237,287,269],"Laparoscopic Appendectomy","Laparoscopic Hernia Repair Surgery",{"date":247,"type":36},{"date":272,"type":23},{"date":251,"type":23},{"name":42,"class":43},{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":230,"enrollmentInfo":299,"targetDuration":4,"studyType":24,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":309,"leadSponsor":311,"locationsCount":149},"100642912","pre-incisional-infiltration-with-ropivacaine-plus-triamcinolone-for-relieving-postoperative-pain-after-thoracoscopic-surgery-100642912","NCT07603921","Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Thoracoscopic Surgery","The Efficacy and Safety of Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone in Patients Undergoing Video-assisted Thoracoscopic: a Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients scheduled for elective thoracoscopic wedge resection, segmentectomy, and lobectomy under general anesthesia;\n2. Ages 18 to 64 years old\n3. American Society of Anesthesiologists (ASA) physical status of I-III\n4. Patients must be able to understand nature and potential personal consequences of the clinical trial and cooperation with follow-up investigations\n5. signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of allergies to experimental drugs such as opioids or steroids;\n2. Alcohol abuse; Long term use of opioid drugs (exceeding 2 weeks or 3 days per week for more than 1 month); Suspected use of sedatives and analgesics; Use analgesic drugs within 24 hours before surgery; Patients undergoing steroid therapy;\n3. Serious neurological disorders, severe liver and kidney dysfunction, heart failure, etc;\n4. Unable to use pain assessment scale;\n5. Pregnant or lactating patients.",{"count":261,"type":23},[86],"Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy, but it is still reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process. If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Acute pain after VATS is mainly caused by the release of inflammatory mediators after soft tissue injury at the surgical site, which activates peripheral pain receptors and leads to abnormal action potentials transmitted along A δ and C fibers. Inflammatory mediators released from the soft tissues around incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization. Incisional infiltration is the simplest, safest, and most effective anesthesia method for preventing incision pain after laparoscopic surgery but even using long-acting local anesthetics, the effectiveness of postoperative analgesia can only last for a relatively short period of time. To improve the efficiency of local incision infiltration in postoperative analgesia, at least two issues need to be addressed: prolonging the duration of analgesia and reducing inflammation of nerve surrounding tissues.\n\nNumerous studies have shown that glucocorticoids not only can achieve anti-inflammatory and analgesic effects by inhibiting inflammatory cytokines and inflammatory responses but also can prolong the duration of action of local anesthetics. The investigators conducted a multicenter, prospective, randomized controlled clinical study to explore whether preemptive incisional infiltration with ropivacaine plus triamcinolone is superior to ropivacaine alone in relieving postoperative pain for adults undergoing VATS. The investigators also compare the effects of the two intervention measures on postoperative pain management, patient safety, and recovery quality.",[265,266,267,303,304,305],"Lobectomy of the Lungs","Incisional Infiltration","Triamcinolone","2026-06-15",{"date":245,"type":36},{"date":249,"type":36},{"date":310,"type":23},"2028-03-31",{"name":42,"class":43},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":18,"minAge":320,"maxAge":202,"enrollmentInfo":321,"targetDuration":4,"studyType":24,"phases":323,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":333,"leadSponsor":334,"locationsCount":149},"100641069","high-density-flexible-ecog-for-epilepsy-surgery---a-single-arm-ect-100641069","NCT07656857","High-density Flexible ECoG for Epilepsy Surgery - A Single-Arm ECT","Precision Resection of the Epileptogenic Zone Using Intraoperative Subdural High-density Flexible Electrocorticography - A Single-Arm Trial With an External Historical Control Cohort","PRECISE","Inclusion Criteria:\n\n1. Aged 3 to 60 years.\n2. Diagnosed with drug-resistant epilepsy, defined as persistent seizures despite treatment with two or more appropriately selected, adequately dosed, and adequately tried antiseizure medications.\n3. Diagnosed with focal epilepsy after a standard presurgical epilepsy evaluation and considered suitable for resective epilepsy surgery.\n4. Preoperative Mini-Mental State Examination (MMSE) score ≥ 24.\n5. Able to provide written informed consent, or written informed consent provided by a legal guardian when applicable.\n\nExclusion Criteria:\n\n1. Suspected mesial temporal lobe epilepsy after multidisciplinary presurgical evaluation.\n2. History of any previous neurosurgical craniotomy before epilepsy surgery.\n3. Severe psychiatric, cognitive, or psychological disorder that prevents participation in the study or completion of follow-up.\n4. Contraindication to surgery.","3 Years",{"count":322,"type":23},85,[86],"What's the clinical value of high-density flexible electrocorticography (ECoG) for guiding the resection of epileptogenic zone (EZ) in epilepsy surgery?",[326],"Focal Epilepsy",[328,329],"Epilepsy surgery","High-density Flexible Electrocorticography",{"date":331,"type":36},"2026-06-18",{"date":68,"type":23},{"date":72,"type":23},{"name":42,"class":43},{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":230,"enrollmentInfo":342,"targetDuration":4,"studyType":24,"phases":344,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":351,"leadSponsor":353,"locationsCount":105},"100642731","the-efficacy-and-safety-of-loxoprofen-sodium-patch-in-relieving-postoperative-pain-after-laparoscopic-surgery-100642731","NCT07591207","The Efficacy and Safety of Loxoprofen Sodium Patch in Relieving Postoperative Pain After Laparoscopic Surgery","The Efficacy and Safety of Incisional Preemptive Analgesia Using Loxoprofen Sodium Patch in Patients Undergoing Laparoscopic Surgery: a Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients scheduled for elective Laparoscopic Surgery for laparoscopic cholecystectomy, appendectomy, or hernia repair under general anesthesia;\n2. Ages 18 to 64 years old\n3. American Society of Anesthesiologists (ASA) physical status of I-III\n4. Patients must be able to understand the nature and potential personal consequences of the clinical trial and cooperate with follow-up investigations\n5. signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of chronic pain syndrome of any cause and mental illness\n2. Excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks or 3 days per week for more than 1 month), use of drugs with confirmed or suspected sedative or analgesic effects, or use of any painkiller within 24 h before surgery.\n3. History of hypertension (Grade 3, extremely high risk)\n4. Pregnancy or breastfeeding.\n5. Extreme body mass index (BMI) (\\\u003C 15 or \\> 35).\n6. Participation in another interventional trial that interferes with the intervention or outcome of this trial.\n7. Digestive system diseases (such as peptic ulcers, gastric bleeding).\n8. Patients with coronary artery disease.\n9. Patients with renal impairment (serum creatinine \\> 176 µmol\u002FL) and abnormal liver function(alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 2× the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5×ULN).\n10. Subjects with coagulation dysfunction (prothrombin time or activated partial thromboplastin time is higher than the normal threshold) or patients who are taking oral anticoagulants for other medical reasons and have not stopped it before surgery, such as warfarin or new anticoagulants rivaroxaban or dabigatran.\n11. Patients with a history of allergy to anyone of the study drugs.",{"count":343,"type":23},134,[86],"Studies have shown that up to 80% of patients experience postoperative pain following laparoscopic surgery due to inflammation caused by surgical incisions and surrounding tissues, necessitating pharmacological relief. Inflammatory mediators released from the soft tissues around laparoscopic incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization.\n\nThe investigators conducted a multicenter, prospective, randomized controlled clinical study to explore the use of Loxoprofen Sodium Patch for preoperative local incision analgesia in laparoscopic surgery patients. The investigators aim to observe whether this method can effectively alleviate postoperative incision pain, reduce the dosage of postoperative analgesics and the side effects caused using postoperative analgesics, improve patient satisfaction, and provide new ideas for postoperative analgesia in laparoscopic surgery patients, promoting rapid recovery after laparoscopic surgery.",[347,348,237,238,239],"Loxoprofen Sodium Patch","Local Incision",{"date":245,"type":36},{"date":249,"type":36},{"date":352,"type":23},"2028-05-31",{"name":42,"class":43},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":24,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":370,"leadSponsor":372,"locationsCount":4},"100641753","oliceridine-for-gastrointestinal-dysfunction-100641753","NCT07650812","Oliceridine for Gastrointestinal Dysfunction","The Effect of Oliceridine on Gastrointestinal Dysfunction and Pain Management in Patients Undergoing Neurosurgery: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients undergoing selective neurosurgical resection of craniocerebral tumors;\n* Age ≥ 18 years old;\n* American Society of Anesthesiologists (ASA) grade 1-3;\n* Sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients unable to complete scale assessment due to preoperative language dysfunction or communication impairment;\n* Patients with preoperative symptoms of posterior cranial nerve injury and who need to retain a tracheal tube;\n* Patients with insular, brainstem, or medullary lesions that may impair early postoperative recovery of consciousness;\n* Patients undergoing intracranial lesion resection via the transsphenoidal approach;\n* Patients with a history of previous abdominal surgery;\n* Patients with BMI \\> 35.0 kg\u002Fm2;\n* Patients with liver or kidney dysfunction;\n* Patients with a history of allergic or adverse reactions to the test drug;\n* Patients with a history of drug abuse;\n* Pregnant or lactating women.",{"count":362,"type":23},176,[86],"Gastrointestinal dysfunction is common in patients after major surgery, especially for neurosurgery. It was reported 80% of neurosurgery patients could be combined with gastrointestinal dysfunction, and it may relate to old age, surgery time, and factors of anesthesia and surgery. Meanwhile, postoperative constipation, nausea, and vomiting induced by gastrointestinal dysfunction may increase the intracranial bleeding. Oliceridine could activate mu opioid receptors without the interaction of (beta)arr2-muOR, and may reduce the gastrointestinal dysfunction, but a limited study has illustrated this topic. Thus, this study is conducted to explore whether oliceridine could reduce the gastrointestinal dysfunction vs. sufentanil in patients undergoing neurosurgery.",[366],"Gastrointestinal Dysfunction","2026-06-14",{"date":245,"type":36},{"date":68,"type":23},{"date":371,"type":23},"2027-12-30",{"name":42,"class":43},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":380,"targetDuration":4,"studyType":24,"phases":382,"briefSummary":384,"conditions":385,"keywords":390,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":105},"100642374","early-phase-1-dosimetry-safety-and-efficacy-study-of-177lulu-xt771-in-patients-with-recurrent-glioblastoma-100642374","NCT07648823","Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma","An Investigator-Initiated Trial to Evaluate the Dosimetry, Safety, Tolerability, and Preliminary Efficacy of a Single-Dose [177Lu]Lu-XT771 Injection in Patients With Recurrent Glioblastoma","Inclusion Criteria:\n\n1. Subject has fully understood the study and voluntarily signed the informed consent form.\n2. Age ≥ 18 and ≤ 80 years old.\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.\n4. Life expectancy of at least 3 months.\n5. Histologically confirmed glioblastoma (based on the 2021 WHO Classification of Tumors of the Central Nervous System, 5th edition), and confirmed CA IX\u002FCA XII positive by histology or \\[68Ga\\]Ga-XT771 PET\u002FCT.\n6. Histologically confirmed recurrence of glioblastoma following prior treatments.\n7. Suitable for Ommaya reservoir placement and meets the conditions for drug administration, as judged by the investigator.\n8. Tumor resection cavity volume between 2.5 and 25 cm\\^3.\n9. On a stable or decreasing dose of corticosteroids (≤5 mg\u002Fday of dexamethasone or equivalent) for at least 1 week prior to the first dose.\n10. Toxicity from prior anti-tumor treatments (e.g., chemotherapy, radiotherapy, immunotherapy) recovered to ≤ Grade 1 (excluding alopecia).\n11. Adequate organ and bone marrow function meeting the following criteria:\n\n    * Bone marrow: Absolute neutrophil count (ANC) ≥ 1.5 ×10\\^9\u002FL and white blood cell (WBC) count ≥ 3 ×10\\^9 \u002FL (without growth factor support within 28 days prior to dosing); Platelet count ≥ 75 ×10\\^9\u002FL; Hemoglobin ≥ 90 g\u002FL.\n    * Hepatic function: Total bilirubin ≤ 1.5 × ULN (≤ 2.0 × ULN for subjects with liver metastases; ≤ 3.0 × ULN for subjects with confirmed Gilbert's syndrome); ALT and AST ≤ 3 × ULN (\\\u003C 5 × ULN for subjects with liver metastases); Albumin \\> 30 g\u002FL.\n    * Renal function: Serum creatinine ≤ 1.5 × ULN and creatinine clearance rate ≥ 50 mL\u002Fmin.\n    * Coagulation: INR ≤ 2.0, APTT ≤ 1.5 × ULN. (Exception: subjects receiving warfarin may have an INR between 2 and 3 inclusive).\n12. Fertile subjects (and their partners) must agree to use highly effective contraceptive methods (e.g., condoms, oral or injectable contraceptives) during the treatment period and for 6 months after the last dose of the study drug.\n\nExclusion Criteria:\n\n1. Received anti-tumor treatments (including radiotherapy, chemotherapy, biological therapy, endocrine therapy, targeted therapy, etc.) within 4 weeks prior to dosing. Exceptions: (1) immunotherapy, nitrosoureas, or mitomycin C within 6 weeks prior to dosing; (2) oral fluorouracils and small molecule targeted drugs within 2 weeks or 5 half-lives (whichever is longer) prior to dosing; (3) Traditional Chinese Medicine with anti-tumor indication within 2 weeks prior to dosing; (4) cranial radiotherapy within 3 months prior to dosing.\n2. Received any other unapproved investigational drug within 4 weeks prior to dosing.\n3. Underwent major organ surgery (excluding needle biopsy) or experienced significant trauma within 4 weeks prior to dosing, or expected to require elective surgery during the study period.\n4. Known or suspected allergy to the study drug or its analogue components.\n5. Inability to undergo contrast-enhanced MRI scans (e.g., due to pacemakers, contrast agent allergy).\n6. Presence of active or uncontrolled infections requiring systemic intravenous treatment, or unexplained fever \\>38.5°C during the screening period or before dosing.\n7. Presence of severe coagulation disorders or evidence of significant bleeding risk; history of gastrointestinal bleeding; any Grade ≥2 bleeding event (CTCAE v5.0) within the past 6 months.\n8. Active Hepatitis B (HBsAg positive and HBV-DNA \\> 500 IU\u002FmL or above the lower limit of detection of the study center) or Active Hepatitis C (HCV antibody positive and HCV-RNA \\> the lower limit of detection of the study center).\n9. Uncontrolled hypertension as judged by the investigator (systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg despite standard treatment).\n10. History of severe cardiovascular disease, such as ventricular arrhythmias requiring clinical intervention; QTc interval \\> 480 ms; acute coronary syndrome, congestive heart failure, stroke, or other ≥ Grade III cardiovascular events within 6 months prior to dosing; NYHA class II-IV or LVEF \\\u003C 50%.\n11. History of other uncured malignancies within the past 3 years or concurrently, except for curable in situ cancers (e.g., carcinoma in situ of the cervix, basal cell carcinoma of the skin).\n12. Presence of two or more intracranial lesions, extracranial metastases, or tumors located in the infratentorial compartment or basal ganglia.\n13. Brain MRI indicating that the enhancing edge of the tumor invades the ventricular wall, or the surgical cavity communicates with the ventricle.\n14. Psychiatric disorders or poor compliance.\n15. Pregnant or lactating women.\n16. The investigator considers the subject unsuitable for participation in this clinical study due to other severe systemic diseases or other reasons.",{"count":381,"type":23},5,[383],"EARLY_PHASE1","The primary objective of this study is to evaluate the dosimetry, safety, and tolerability of the investigational radiopharmaceutical \\[177Lu\\]Lu-XT771 in patients with recurrent glioblastoma, an aggressive form of brain cancer. \\[177Lu\\]Lu-XT771 is designed to specifically target and deliver beta radiation directly to tumor cells that overexpress carbonic anhydrase IX and XII (CA IX and CA XII).\n\nThis early-phase, investigator-initiated trial will enroll a small group of approximately 3-5 patients, each receiving a single dose of \\[177Lu\\]Lu-XT771. The drug will be administered locoregionally via an implanted Ommaya reservoir, directly into the tumor cavity. Following administration, patients will be closely monitored using single-photon emission computed tomography\u002Fcomputed tomography (SPECT\u002FCT) to assess the biodistribution of the drug and to quantify the absorbed radiation dose to both the tumor and normal organs.\n\nThe study will also document all adverse events to characterize the safety profile of the treatment and will provide a preliminary assessment of its anti-tumor activity, as measured by progression-free survival. The information gathered from this exploratory study will be used to determine the recommended safe starting dose for future Phase I clinical trials.",[386,387,388,389],"Recurrent Glioblastoma (WHO-Grade IV Glioma)","Recurrent Glioblastoma","Glioblastoma (GBM)","Recurrent Glioblastoma IDH Wildtype",[387,391,392,393,394,395,396],"[177Lu]Lu-XT771","Carbonic Anhydrase IX","Carbonic Anhydrase XII","Safety and Tolerability","Dosimetry","Efficacy","2026-06-13",{"date":245,"type":36},{"date":400,"type":23},"2026-06-20",{"date":402,"type":23},"2028-06-01",{"name":42,"class":43},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":24,"phases":413,"briefSummary":414,"conditions":415,"keywords":417,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":423,"leadSponsor":425,"locationsCount":105},"100641259","early-phase-1-177lulu-dota-eb-rgd2-therapy-in-patients-with-recurrent-high-grade-glioma-100641259","NCT07655869","[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma","An Investigator-Initiated Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of [177Lu]Lu-DOTA-EB-RGD2 in Patients With Recurrent High-grade Glioma","Inclusion Criteria:\n\n1. The participant must sign the informed consent form before participation.\n2. Age ≥ 18 years.\n3. Histologically confirmed glioblastoma (WHO classification) after surgical resection or biopsy.\n4. Participants receiving corticosteroids (e.g., dexamethasone) must be on a stable or decreasing dose ≤ 4 mg\u002Fday (or equivalent) for at least 7 days before start of study treatment.\n5. Adequate bone marrow and organ function confirmed by laboratory tests performed ≤ 14 days before first study treatment:\n\n   Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL; Platelet count ≥ 100 × 10⁹\u002FL; Hemoglobin ≥ 10.0 g\u002FdL; Serum creatinine ≤ 1.5 × upper limit of normal (ULN); Total bilirubin ≤ 1.5 × ULN; albumin ≥ 30 g\u002FL; ALT and AST \\\u003C 3 × ULN in absence of liver metastases, or \\\u003C 5 × ULN if liver metastases present; Coagulation: activated partial thromboplastin time (APTT) ≤ 2 × ULN, international normalized ratio (INR) ≤ 1.5 (if not receiving anticoagulation therapy);\n6. Evidence of disease progression (PD) by RANO 2.0 criteria confirming recurrence: ≥ 25% increase in product of perpendicular diameters or \\> 40% increase in tumor volume compared to baseline after initial treatment or best response, while on stable or increasing corticosteroid dose. Clinical deterioration or increased corticosteroid dose alone is insufficient. MRI contrast enhancement, MRS, and\u002For metabolic PET should help differentiate true progression from radiation necrosis\u002Fpseudoprogression. Also, at least one bi-dimensionally measurable contrast-enhancing lesion with shortest diameter ≥ 10 mm must be present on MRI.\n7. For participants receiving Ommaya reservoir implantation for locoregional administration, surgery must be completed at least 2 weeks before first radionuclide therapy, with no postoperative complications. Baseline MRI for efficacy assessment must be performed at least 2 weeks after implantation and before first radionuclide therapy.\n8. Tumor uptake confirmed by NOTA-PRGD2 PET\u002FCT after diagnosis of recurrence and before radionuclide therapy. For participants with Ommaya reservoir, PET\u002FCT must be performed at least 2 weeks after implantation and before first radionuclide therapy.\n9. Life expectancy \\> 6 months.\n10. Karnofsky Performance Status (KPS) score ≥ 50.\n\nExclusion Criteria:\n\n1. Receiving any other concurrent treatment for glioblastoma outside this study.\n2. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed from the start of \\[177Lu\\]Lu-DOTA-EB-RGD2 treatment until 6 months after treatment.\n3. Refusal to use effective contraception during sexual intercourse from informed consent until 6 months after the last dose of study drug.\n4. Inability to tolerate imaging procedures, repeated blood sampling, or poor venous access.\n5. Cardiac dysfunction, clinically significant cardiac disease history, or ECG abnormalities indicating a major safety risk, including:\n\n(1) Documented myocardial infarction, angina pectoris, cardiomyopathy, symptomatic pericarditis, or coronary artery bypass grafting within 6 months before enrollment.\n\n(2) Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following: (a) risk factors for torsade de pointes (TdP) including uncorrected hypocalcemia, hypokalemia, hypomagnesemia, history of heart failure, or clinically significant\u002Fsymptomatic bradycardia; (b) use of medications known to prolong the QT interval and\u002For cause TdP that cannot be discontinued or replaced with a safer alternative (e.g., within 5 half-lives or 7 days before study drug); (c) inability to determine the Fridericia-corrected QT interval (QTcF).\n\n(3) Clinically significant arrhythmia (e.g., ventricular tachycardia), complete left bundle branch block, high-grade atrioventricular block (e.g., bifascicular block, Mobitz type II, third-degree AV block).\n\n(4) Resting QTcF ≥ 450 ms (male) or ≥ 460 ms (female). (5) Left ventricular ejection fraction (LVEF) \\\u003C 50% by echocardiography. (6) Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg, regardless of antihypertensive use.\n\n6\\. Other malignancy within 5 years before study drug administration, except adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer after curative surgery, carcinoma in situ after curative surgery, or papillary thyroid cancer after curative surgery (hormonal therapy for non-metastatic prostate or breast cancer allowed).\n\n7\\. Abnormal serum virology (HBsAg, T. pallidum antibody, HIV antibody, HCV antibody). Patients with untreated active hepatitis B who are willing to receive anti-HBV therapy during study treatment are allowed; patients with inactive hepatitis B are allowed; patients with inactive hepatitis C (HCV antibody positive but HCV RNA below lower limit of detection) are allowed.\n\n8\\. Use of bevacizumab for glioblastoma or supportive care (e.g., edema reduction) within 60 days before start of study treatment.\n\n9\\. Patients with disease progression within the first 12 weeks after completion of radiotherapy are excluded from recurrent disease trials.\n\n10\\. Prior intracranial locoregional drug therapy before \\[177Lu\\]Lu-DOTA-EB-RGD2 treatment.\n\n11\\. Active intracranial or intratumoral hemorrhage detected by CT\u002FMRI. 12. Seizure within 14 days before start of study treatment; epilepsy or increased intracranial pressure uncontrolled by medication.\n\n13\\. Grade 4 myelosuppression from prior anticancer therapy that has not recovered within 2 weeks, or grade 3 myelosuppression requiring \\>6 weeks to recover.\n\n14\\. Blood transfusion within 4 weeks before screening to meet eligibility criteria.\n\n15\\. Known hypersensitivity or delayed allergic reaction to any component of \\[177Lu\\]Lu-DOTA-EB-RGD2 or similar drugs.\n\n16\\. Severe disease of the cardiac, respiratory, central nervous system, renal, hepatic, or other organ systems that, in the investigator's opinion, may increase participant safety risk.\n\n17\\. Active infection requiring intravenous antibiotics (bacterial, fungal, or viral) within 4 weeks before first dose, or any other uncontrolled active infection deemed clinically significant by the investigator.\n\n18\\. History of drug or alcohol abuse within one year before screening, long-term drug use, or psychiatric illness that may affect compliance.\n\n19\\. Participation in another investigational drug or device trial within 4 weeks before first dose.",{"count":412,"type":23},24,[383],"This is an investigator-initiated, Phase I clinical trial. It aims to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of a novel radiopharmaceutical, \\[177Lu\\]Lu-DOTA-EB-RGD2, in patients with recurrent high-grade gliomas. Participants will receive the drug either via intravenous infusion or directly into the tumor cavity through a pre-implanted Ommaya reservoir (a subcutaneously placed device that allows direct access to the tumor cavity). The study employs a \"3+3\" dose-escalation design to determine the maximum tolerated dose (MTD). Adverse events, biodistribution, and tumor response (by MRI) will be assessed. Approximately 24 patients will be enrolled across two major Chinese medical centers: Beijing Tiantan Hospital and Peking Union Medical College Hospital.",[416,389],"Recurrent High-Grade Gliomas",[416,418,419,394,420],"Integrin αvβ3","Targeted Radionuclide Therapy","Radiation Dosimetry",{"date":331,"type":36},{"date":249,"type":23},{"date":424,"type":23},"2027-01-31",{"name":42,"class":43},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":434,"targetDuration":4,"studyType":24,"phases":436,"briefSummary":438,"conditions":439,"keywords":441,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":450,"leadSponsor":451,"locationsCount":149},"100642716","phase-2-a-phase-2b-trial-of-lesion-network-mapping-guided-ctbs-for-motor-recovery-after-acute-ischemic-stroke-100642716","NCT07645560","A Phase 2b Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic Stroke","Lesion Network Mapping-Navigated Continuous Theta-Burst Stimulation for Motor Recovery in Acute Ischemic Stroke: A Randomized, Double-Blind, Sham-Controlled, Multicentre Phase 2b Trial: MASTRE-2","MASTRE-2","Inclusion Criteria:\n\n1. Age 18-80 years.\n2. Ischemic stroke onset within the past 14 days.\n3. Unilateral, supratentorial ischemic stroke confirmed by CT or MRI.\n4. Pre-stroke modified Rankin Scale (mRS) score of 0-1.\n5. NIH Stroke Scale (NIHSS) total score 6-25, with item 1a ≤ 1 point, and at least one of items 5a, 5b, 6a, or 6b ≥ 2 points.\n6. Written informed consent signed by the patient or the patient's legally authorized representative.\n\nExclusion Criteria:\n\n1. Contraindications to TMS (e.g. cranial metallic foreign bodies, cardiac pacemaker, implanted drug pump, cochlear implant).\n2. History of epilepsy or seizure, intracranial hypertension, tumor, or other serious neurological disease.\n3. Midline shift or parenchymal mass effect on cranial CT or other imaging.\n4. CT or MRI evidence of bilateral acute cerebral infarction or infratentorial acute infarction (brainstem or cerebellum).\n5. Evidence of acute intracranial hemorrhage, including spontaneous intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage.\n6. Pre-stroke mRS ≥ 2.\n7. Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg despite antihypertensive treatment.\n8. Pregnant or breastfeeding women, or women planning pregnancy within 90 days.\n9. Severe psychiatric disorders or dementia (or other conditions) precluding informed consent or follow-up.\n10. Concomitant malignant tumor or severe systemic disease with life expectancy \\\u003C 90 days.\n11. Participation in any other interventional clinical study within 30 days before randomization, or currently enrolled in such a study.",{"count":435,"type":23},60,[437],"PHASE2","This Phase 2b study will evaluate whether lesion network mapping-guided continuous theta burst stimulation (cTBS) can improve recovery after acute ischemic stroke. The treatment uses each participant's brain imaging to identify individualized stimulation targets related to stroke symptoms. Participants will receive either active cTBS or a sham procedure in addition to standard stroke care. The study will assess the efficacy and safety of this personalized brain stimulation approach and support planning for future confirmatory trials.",[440],"Ischemic Stroke",[442,443,444,445,446],"ishchemic stroke","Lesion network mapping","Continuous theta-burst stimulation","Motor function","Neuronavigation","2026-06-12",{"date":306,"type":36},{"date":306,"type":23},{"date":371,"type":23},{"name":42,"class":43},{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":459,"targetDuration":4,"studyType":24,"phases":461,"briefSummary":462,"conditions":463,"keywords":464,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":465,"startDateStruct":466,"completionDateStruct":467,"leadSponsor":468,"locationsCount":149},"100642075","phase-3-a-phase-3-trial-of-lesion-network-mapping-guided-ctbs-for-motor-recovery-after-acute-ischemic-stroke-100642075","NCT07645586","A Phase 3 Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic Stroke","Lesion Network Mapping-Navigated Continuous Theta-Burst Stimulation for Motor Recovery in Acute Ischemic Stroke: A Randomized, Double-Blind, Sham-Controlled, Multicentre Phase 3 Trial: MASTRE-3","MASTRE-3",{"count":460,"type":23},584,[55],"This Phase 3 study will evaluate whether lesion network mapping-guided continuous theta burst stimulation (cTBS) can improve recovery after acute ischemic stroke. The treatment uses each participant's brain imaging to identify individualized stimulation targets related to stroke symptoms. Participants will receive either active cTBS or a sham procedure in addition to standard stroke care. The study will assess whether this personalized brain stimulation approach improves functional recovery and is safe for patients after ischemic stroke.",[440],[442,443,444,445,446],{"date":306,"type":36},{"date":306,"type":23},{"date":371,"type":23},{"name":42,"class":43},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":476,"sex":18,"minAge":477,"maxAge":478,"enrollmentInfo":479,"targetDuration":481,"studyType":482,"phases":4,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":493,"locationsCount":149},"100370705","clinical-and-imaging-cohort-of-neuroinflammation-diseases-in-china-clue-100370705","NCT04106830","Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)","Prospective Cohort Study of cLinical and Imaging Patterns of neUroinflammation disEases (CLUE)","Inclusion Criteria:\n\n* 16-75\n* Diagnosis of neuroinflammatory and demyelination disease\n* Availability of demographic and clinical data at the time disease onset\n* Informed written consent obtained from the patient, and\u002For patient's parent(s), and\u002For legal representative. Assent, if old enough to grant, will be obtained from all patients under the age of 16 years.\n\nExclusion Criteria:\n\n* Patients for whom MRI is contra-indicated\n* Patients included in an ongoing clinical trial where the product is blinded",true,"16 Years","75 Years",{"count":480,"type":23},1000,"12 Months","OBSERVATIONAL","CLUE is a prospective study to assess structural and functional changes of the brain, spinal cord, and optic nerve, as well as the inflammatory environment in patients with neuroinflammatory and demyelinating diseases. Participants will receive magnetic resonance (MR) techniques including DIR, DKI, QSM, Rs-fMRI, conventional sequences (T1WI\u002FT2WI\u002FFLAIR), and the MR metabolic SPICE sequence, and will be followed up for one year using 3T MRI. In addition, participants will receive a one-time baseline examination including T1WI, T2WI, FLAIR, and SWI sequences on 7T MRI, as well as PET-MRI.",[485,486,487,488],"NMO Spectrum Disorder","MRI","Multiple Sclerosis","MOGAD",{"date":306,"type":36},{"date":491,"type":36},"2019-01-01",{"date":72,"type":23},{"name":42,"class":43},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":501,"enrollmentInfo":502,"targetDuration":4,"studyType":24,"phases":504,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":512,"completionDateStruct":513,"leadSponsor":514,"locationsCount":149},"100641500","stellate-ganglion-block-and-prognosis-of-neurological-function-after-subarachnoid-hemorrhage-100641500","NCT07652749","Stellate Ganglion Block and Prognosis of Neurological Function After Subarachnoid Hemorrhage","Effect of Stellate Ganglion Block on the Prognosis of Neurological Function After Subarachnoid Hemorrhage","Inclusion Criteria:\n\n* Age range: 18-65 years old;\n* Within 72 hours after onset of aSAH,and planning surgical treatment(aneurysm embolizing or clipping);\n* Preoperative Hunt-Hess grade 2-3\n* Sign informed consent.\n\nExclusion Criteria:\n\n* ASA \\> grade IV;\n* Patients with posterior circulation aneurysm;\n* Patients with severe systemic hemorrhagic diseases;\n* Patients with trauma and local infection in the nerve block area;\n* Local anatomic structure changes (neck structure changes caused by radiotherapy, chemotherapy and surgery);\n* Allergy to known local anesthetics;\n* Pregnant and lactating women.","65 Years",{"count":503,"type":23},560,[86],"The incidence of cerebral vasospasm after aneurysm subarachnoid hemorrhage (aSAH) is as high as 70%; cerebral vasospasm（CVS） is closely related to delayed cerebral ischemia （DCI）, which is one of the important reasons for poor outcomes in patients with aSAH.\n\nIn recent years, it has been reported that stellate ganglion block(SGB) can effectively alleviate cerebral vasospasm(CVS), reduce cerebral blood flow velocity and increase cerebral perfusion in patients with aneurysm subarachnoid hemorrhage(aSAH)。However, whether the alleviation of CVS after SGB is beneficial to the long-term neurological prognosis has not been confirmed Therefore, a prospective randomized controlled study is needed to further explore the role of SGB block in improving the outcomes of patients with aSAH.",[507,508,509],"Aneurysmal Subarachnoid Hemorrhage","Stellate Ganglion Block","Neurological Prognosis","2026-06-11",{"date":247,"type":36},{"date":306,"type":23},{"date":147,"type":23},{"name":42,"class":43},{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":501,"enrollmentInfo":522,"targetDuration":4,"studyType":24,"phases":524,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":535,"locationsCount":149},"100620761","comparison-of-cumulative-opioid-consumption-between-variable-rate-feedback-infusion-and-fixed-rate-basal-infusion-modes-of-intravenous-pca-following-mixed-surgery-100620761","NCT07361822","Comparison of Cumulative Opioid Consumption Between Variable-Rate Feedback Infusion and Fixed-Rate Basal Infusion Modes of Intravenous PCA Following Mixed Surgery","Prospective Randomized Controlled Study of Individualized PCA Model Based on Multi-dimensional Strategies (Cumulative Opioid Consumption Between Variable-Rate Feedback Infusion and Fixed-Rate Basal Infusion Modes)","Inclusion Criteria:\n\n* aged between 18 to 65 years;\n* American Society of Anesthesiologists physical status Ⅰ - Ⅲ;\n* Patients scheduled for elective mixed surgery were enrolled. Mixed surgeries included thoracic, abdominal, spinal, orthopaedic, and cranial procedures performed using either minimally invasive or open approaches.\n\nExclusion Criteria:\n\n* Allergy to PCA medications;\n* Presence of chronic pain syndromes;\n* Presence of psychiatric disorders, or severe cardiovascular, cerebrovascular, renal, or hepatic dysfunction.",{"count":523,"type":23},1170,[86],"Perioperative pain management affects patient recovery. However, the rate of moderate to severe postoperative pain is as high as 73.8%, which hinders recovery and increases the risk of complications. Although opioids are the first-line analgesics, excessive use leads to adverse reactions. The traditional fixed-rate PCA mode is difficult to match the changes in postoperative pain. This study will compare different PCA mode optimization strategies, assuming that they can reduce opioid dosage, improve analgesic effect, and reduce adverse reactions, providing high-quality evidence-based basis for postoperative analgesia and promoting individualized and intelligent management.",[527,528,529,530],"Surgery","Pain Management","Opioid Consumption","Patient-controlled Analgesia",{"date":447,"type":36},{"date":533,"type":36},"2025-12-30",{"date":371,"type":23},{"name":42,"class":43},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":158,"maxAge":544,"enrollmentInfo":545,"targetDuration":4,"studyType":24,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":4},"100642975","phase-1-a-study-of-the-metabolic-reconstruction-oral-biologics-gut-x-001-medication-in-people-with-alzheimers-disease-escape-ad-100642975","NCT07591727","A Study of the Metabolic Reconstruction Oral Biologics (Gut-X-001) Medication in People With Alzheimer's Disease (ESCAPE-AD)","Efficacy, Safety, and Feasibility of Metabolic ReConstruction Oral Biologics (Gut-X-001) in Patients With Alzheimer's Disease: An Exploratory Clinical Trial （ESCAPE-AD）","ESCAPE-AD","Inclusion Criteria\n\n1. Age ≥50 and ≤85 years.\n2. Diagnosis of Alzheimer's disease confirmed by a qualified neurologist based on the 2024 National Institute on Aging - Alzheimer's Association (NIA-AA) diagnostic criteria, with at least one abnormal core biomarker, including amyloid PET, CSF Aβ42\u002F40, phosphorylated tau181 (p-tau181)\u002FAβ42, total tau (t-tau)\u002FAβ42, or plasma p-tau217.\n3. MMSE score meeting the following criteria:\n\n   If years of education ≤6: MMSE score between 16 and 24 (inclusive); If years of education \\>6: MMSE score between 18 and 27 (inclusive).\n4. Clinical Dementia Rating (CDR) global score of 0.5 (for MCI due to AD) or 1.0 (for mild AD dementia).\n5. If receiving acetylcholinesterase inhibitor (AChEI) and\u002For memantine therapy, the dose must have been stable for at least 3 months prior to screening.\n6. Participants must have a reliable caregiver who has frequent contact with the participant (at least 4 days per week and at least 2 hours per day). The caregiver must accompany the participant to all study visits, provide meaningful input for scale assessments through sufficient interaction with the participant, and remain consistent throughout the study period wherever possible.\n7. The participant or their legally authorized representative is able and willing to provide written informed consent.\n\nExclusion Criteria\n\n1. Presence of other conditions that may contribute to cognitive impairment, including neurological disorders (e.g., vascular cognitive impairment, Parkinson's disease, frontotemporal dementia, Lewy body dementia) or psychiatric and affective disorders (e.g., severe anxiety\u002Fdepression, schizophrenia).\n2. Diagnosis of acute cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, myocardial infarction, or heart failure within the 3 months prior to screening.\n3. Presence of other active or significant neurological conditions, including recurrent epileptic seizures, intracranial space-occupying tumors, vascular malformations (including arteriovenous malformations, arterial malformations, or cavernous malformations), or untreated aneurysms with a diameter \\>3 mm.\n4. Severe hepatic impairment \\[ALT or AST \\>3× upper limit of normal (ULN), or concurrent acute hepatitis, chronic active hepatitis, or liver cirrhosis\\], renal impairment \\[estimated glomerular filtration rate (eGFR) \\\u003C45 mL\u002Fmin\u002F1.73 m²\\], active malignancy, severe anemia, chronic obstructive pulmonary disease (COPD), immune system disorders, uncontrolled diabetes, or uncontrolled hypertension \\[systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg\\].\n5. Currently receiving medications that may interfere with study outcomes.\n6. Known hypersensitivity to the investigational drug or any of its excipients.\n7. Formal education of 1 year or less.\n8. Known history of severe organic disease or an anticipated survival of less than 12 months.\n9. Pregnant or breastfeeding women, or women of childbearing potential who refuse to use contraceptive measures.\n10. Participation in another clinical study within 30 days prior to screening, or currently enrolled in another clinical study.\n11. Any other condition that, in the investigator's judgment, makes the participant unsuitable for enrollment or unable to complete the study procedures and follow-up visits, such as psychiatric illness or physical conditions that preclude compliance with study requirements.","85 Years",{"count":546,"type":23},120,[26,437],"This is an exploratory clinical trial aimed at preliminarily evaluating the efficacy, safety, and feasibility of orally administered Gut-X-001 in patients with Alzheimer's disease (AD). An open-label extension (OLE) study will also be conducted to further investigate the effects of Gut-X-001. The study will assess the effects of Gut-X-001 on cognitive function, activities of daily living, neuroimaging indicators, and AD-related plasma biomarkers in AD patients. Safety will be systematically monitored, including the incidence of adverse events and changes in hematological and organ function parameters. Furthermore, the study will explore the regulatory effects of Gut-X-001 versus placebo on venous blood redox-related indicators and gut microbiota metabolite levels at different time points, providing a basis for multi-target intervention strategies and offering systematic evidence for the scientific rationale, feasibility, and safety of Gut-X-001 in the clinical management of AD.",[550],"Alzheimer s Disease","2026-06-09",{"date":510,"type":36},{"date":554,"type":23},"2026-08-01",{"date":556,"type":23},"2027-12-01",{"name":42,"class":43},{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":230,"enrollmentInfo":565,"targetDuration":4,"studyType":24,"phases":567,"briefSummary":568,"conditions":569,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":575,"leadSponsor":577,"locationsCount":4},"100642646","the-efficacy-and-safety-of-loxoprofen-sodium-patch-in-relieving-postoperative-pain-after-thoracoscopic-surgery-100642646","NCT07591220","The Efficacy and Safety of Loxoprofen Sodium Patch in Relieving Postoperative Pain After Thoracoscopic Surgery","The Efficacy and Safety of Incisional Preemptive Analgesia Using Loxoprofen Sodium Patch in Patients Undergoing Thoracoscopic Surgery: a Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients scheduled for elective Video-assisted thoracoscopic surgery for wedge resection, segmentectomy and lobectomy of the lungs under general anesthesia;\n2. 8 to 64 years old;\n3. American Society of Anesthesiologists (ASA) physical status of I-III;\n4. Patients must be able to understand the nature and potential personal consequences of the clinical trial and cooperate with follow-up investigations\n5. signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of chronic pain syndrome of any cause and mental illness;\n2. Excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks or 3 days per week for more than 1 month), use of drugs with confirmed or suspected sedative or analgesic effects, or use of any painkiller within 24 h before surgery;\n3. History of hypertension (Grade 3, extremely high risk);\n4. Pregnancy or breastfeeding;\n5. Extreme body mass index (BMI) (\\\u003C 15 or \\> 35);\n6. Participation in another interventional trial that interferes with the intervention or outcome of this trial;\n7. Digestive system diseases (such as peptic ulcers, gastric bleeding);\n8. Patients with coronary artery disease;\n9. Patients with renal impairment (serum creatinine \\> 176 µmol\u002FL) and abnormal liver function(alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 2× the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5×ULN);\n10. Subjects with coagulation dysfunction (prothrombin time or activated partial thromboplastin time is higher than the normal threshold) or patients who are taking oral anticoagulants for other medical reasons and have not stopped it before surgery, such as warfarin or new anticoagulants rivaroxaban or dabigatran;\n11. Patients with a history of allergy to anyone of the study drugs;",{"count":566,"type":23},156,[86],"Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy, but it is still reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process. If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Acute pain after VATS is mainly caused by the release of inflammatory mediators after soft tissue injury at the surgical site, which activates peripheral pain receptors and leads to abnormal action potentials transmitted along A δ and C fibers. Inflammatory mediators released from the soft tissues around incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization. Therefore, drugs with potent local anti-inflammatory properties such as Loxoprofen Sodium may play a key role in preventing or reducing postoperative pain. The investigators conducted a multicenter, prospective, randomized controlled clinical study to explore the use of Loxoprofen Sodium Patch for preoperative local incision analgesia in VATS patients. The investigators aim to observe whether this method can effectively alleviate postoperative incision pain, reduce the dosage of postoperative analgesics and the side effects caused using postoperative analgesics, improve patient satisfaction, and provide new ideas for postoperative analgesia in VATS patients, promoting rapid recovery after VATS.",[265,347,348,570,266,267,268],"Postoperative Pain","2026-06-07",{"date":573,"type":36},"2026-06-10",{"date":249,"type":23},{"date":576,"type":23},"2028-04-30",{"name":42,"class":43},{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":586,"targetDuration":4,"studyType":24,"phases":588,"briefSummary":589,"conditions":590,"keywords":592,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":596,"completionDateStruct":597,"leadSponsor":599,"locationsCount":149},"100643206","phase-1-robot-assisted-hematoma-evacuation-with-intrahematoma-tenecteplase-for-post-reperfusion-ph2-hemorrhagic-transformation-100643206","NCT07641998","Robot-Assisted Hematoma Evacuation With Intrahematoma Tenecteplase for Post-Reperfusion PH2 Hemorrhagic Transformation","A Phase I, Open-Label, Single-Arm Study of Robot-Assisted Stereotactic Minimally Invasive Hematoma Aspiration Followed by Intrahematoma Tenecteplase in Patients With Symptomatic Supratentorial PH2 Hemorrhagic Transformation After Reperfusion Therapy for Acute Ischemic Stroke","REPORT","Inclusion Criteria:\n\n•. Age 18 years or older and younger than 80 years.\n\n* Prestroke modified Rankin Scale score of 0 to 2.\n* Acute ischemic stroke treated with reperfusion therapy (standard-dose intravenous thrombolysis using alteplase or tenecteplase, or mechanical thrombectomy or any other endovascular reperfusion procedure for the index stroke).\n* CT-confirmed symptomatic PH2 hemorrhagic transformation according to ECASS criteria in a supratentorial deep or lobar location, with hematoma-related mass effect and\u002For midline shift.\n* Hematoma volume 20 to 80 mL measured by ABC\u002F2 method.\n* Neurological deterioration attributed to hemorrhagic transformation, defined as an NIHSS increase of 4 points or more from the best post-thrombolysis status or a GCS decrease of 2 points or more.\n* At least one repeat stability CT scan obtained 6 hours or more after the diagnostic CT showing no ongoing rapid expansion, defined as hematoma growth less than 6 mL.\n* Planned robot-assisted stereotactic minimally invasive puncture\u002Faspiration within 24 hours after the diagnostic CT.\n* Completion of intravenous thrombolytic infusion at least 4 hours before final preprocedure assessment, with protocol-based reversal\u002Fcorrection of coagulopathy as needed.\n* Preprocedure coagulation thresholds achieved after reversal\u002Fcorrection: INR \\\u003C 1.4 or less, and fibrinogen \\> 1.6 g\u002FL.\n* Systolic blood pressure 180 mmHg or less maintained for at least 6 hours before the procedure.\n* Written informed consent provided by the participant or legally authorized representative.\n\nExclusion Criteria:\n\n* HI1, HI2, or PH1 hemorrhagic transformation without clinically relevant mass effect.\n* Infratentorial hemorrhage, including brainstem or cerebellar hemorrhage.\n* Large malignant hemispheric infarction in which the dominant cause of mass effect is ischemic edema rather than hematoma, or clear need for decompressive craniectomy as first-line treatment.\n* Hemorrhage primarily attributable to aneurysm, arteriovenous malformation, dural arteriovenous fistula, moyamoya disease, tumor, trauma, or another structural lesion; or hemorrhage caused predominantly by a procedural vascular injury unrelated to thrombolysis-associated hemorrhagic transformation.\n* Intraventricular hemorrhage requiring separate emergency surgical treatment as the dominant lesion.\n* Irreversible brainstem failure, bilateral fixed and dilated pupils, or GCS score of 4 or less.\n* Ongoing hematoma expansion on stability CT, defined as growth of 6 mL or more.\n* Imaging evidence of active bleeding or markedly high rebleeding risk, such as spot sign, if judged unsafe for catheter aspiration.\n* Need for long-term anticoagulation that cannot be safely interrupted during the first 30 days after treatment.\n* No safe robot-planned stereotactic trajectory to the hematoma cavity.\n* Severe hepatic, renal, cardiac, respiratory, or hematologic illness likely to confound assessment or markedly increase procedural risk.\n* Pregnancy or breastfeeding.\n* Known allergy or hypersensitivity to alteplase or tenecteplase.\n* Participation in another interventional clinical trial.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for this study.",{"count":587,"type":23},20,[26],"The purpose of this phase I trial is to evaluate the safety and feasibility of robot-assisted stereotactic minimally invasive hematoma aspiration, followed when eligible by intrahematoma tenecteplase administration, in patients who develop symptomatic supratentorial PH2 hemorrhagic transformation after reperfusion therapy for acute ischemic stroke. The main study questions are whether this strategy is associated with an acceptable early rebleeding risk and whether it can achieve clinically meaningful hematoma reduction with accurate catheter placement and relief of hematoma-related mass effect.",[591],"Hemorrhagic Transformation Stroke",[593],"tenecteplase，Minimally Invasive Surgery，hematoma aspiration，Hemorrhagic Transformation，post-reperfusion","2026-06-06",{"date":510,"type":36},{"date":573,"type":23},{"date":598,"type":23},"2026-12-30",{"name":42,"class":43},""]